Guidelines to cell engineering for monoclonal antibody production

Area of Science:

• Biotechnology
• Biopharmaceutical Manufacturing
• Cell Line Development

Background:

• Monoclonal antibodies (mAbs) are crucial for diagnostics and therapeutics, driving demand for large-scale production.
• Current productivity gains primarily focus on bioreactor optimization, overlooking earlier production stages.

Purpose of the Study:

• To review progress in enhancing productivity within mammalian expression systems for monoclonal antibody (mAb) production.
• To identify key areas for improvement in the early stages of biopharmaceutical manufacturing.

Main Methods:

• Review of recent advances in expression vector design and transfection methods for mAb-producing cell lines.
• Analysis of strategies for improving clone selection beyond mere expression levels.
• Exploration of cell engineering approaches for enhanced cell growth, productivity, and product quality.

Main Results:

• Progress is being made in developing reproducible methodologies for mAb-producing cell lines.
• Enhanced clone selection criteria and cell engineering strategies show potential for significant improvements.
• Optimization of early production steps can lead to higher cell expression ability and faster process development.

Conclusions:

• Improving early-stage production processes in mammalian systems is a promising avenue for increasing monoclonal antibody (mAb) yields.
• Advances in cell line development, clone selection, and cell engineering are critical for future biopharmaceutical manufacturing efficiency.